An in vivo Car-T produced a 100% response rate – in three patients.
ApexOnco Front Page
Recent articles
Rival BTK degraders face off, as do bispecific Cars and T-cell engagers.
Key FDA decisions are expected to face delays.
After trimming its cell therapy pipeline last year, the group is now out entirely.
The Titan CD8-guiding technology seems to have spawned a new variant.
The first pivotal data with raludotatug deruxtecan will feature as a late-breaker.
A Chinese phase 3 of the biparatopic DLL3 T-cell engager alveltamig will start soon.
A single-arm trial was enough for J&J’s Inlexzo nod.
